Royal Bank of Canada’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.85M | Buy |
139,071
+87,213
| +168% | +$2.78M | ﹤0.01% | 2492 |
|
|
2026
Q1 | $1.37M | Sell |
51,858
-393,734
| -88% | -$11.5M | ﹤0.01% | 3383 |
|
|
2025
Q4 | $12.9M | Buy |
445,592
+289,237
| +185% | +$8.68M | ﹤0.01% | 1776 |
|
|
2025
Q3 | $4.34M | Buy |
156,355
+98,903
| +172% | +$2.5M | ﹤0.01% | 2785 |
|
|
2025
Q2 | $1.4M | Sell |
57,452
-63,474
| -52% | -$1.39M | ﹤0.01% | 3610 |
|
|
2025
Q1 | $2.51M | Sell |
120,926
-123,638
| -51% | -$3.11M | ﹤0.01% | 2776 |
|
|
2024
Q4 | $5.76M | Sell |
244,564
-411,028
| -63% | -$10.1M | ﹤0.01% | 2202 |
|
|
2024
Q3 | $16.8M | Buy |
655,592
+417,047
| +175% | +$10.6M | ﹤0.01% | 1454 |
|
|
2024
Q2 | $5.6M | Buy |
238,545
+65,162
| +38% | +$1.64M | ﹤0.01% | 2093 |
|
|
2024
Q1 | $4.99M | Sell |
173,383
-49,403
| -22% | -$1.49M | ﹤0.01% | 2182 |
|
|
2023
Q4 | $7.31M | Sell |
222,786
-11,721
| -5% | -$319K | ﹤0.01% | 1963 |
|
|
2023
Q3 | $6.53M | Buy |
234,507
+16,433
| +8% | +$537K | ﹤0.01% | 1893 |
|
|
2023
Q2 | $7.43M | Sell |
218,074
-16,502
| -7% | -$519K | ﹤0.01% | 1804 |
|
|
2023
Q1 | $7.05M | Buy |
234,576
+44,877
| +24% | +$1.39M | ﹤0.01% | 1820 |
|
|
2022
Q4 | $5.36M | Sell |
189,699
-110,128
| -37% | -$3.5M | ﹤0.01% | 2086 |
|
|
2022
Q3 | $9.86M | Buy |
299,827
+63,846
| +27% | +$2.34M | ﹤0.01% | 1549 |
|
|
2022
Q2 | $7.43M | Sell |
235,981
-73,840
| -24% | -$2.58M | ﹤0.01% | 1783 |
|
|
2022
Q1 | $14.2M | Buy |
309,821
+14,483
| +5% | +$690K | ﹤0.01% | 1475 |
|
|
2021
Q4 | $18.1M | Sell |
295,338
-123,414
| -29% | -$8.53M | ﹤0.01% | 1455 |
|
|
2021
Q3 | $31.3M | Sell |
418,752
-58,117
| -12% | -$4.88M | 0.01% | 1030 |
|
|
2021
Q2 | $44.1M | Buy |
476,869
+41,225
| +9% | +$3.51M | 0.01% | 822 |
|
|
2021
Q1 | $38.7M | Buy |
435,644
+138,207
| +46% | +$13.7M | 0.01% | 833 |
|
|
2020
Q4 | $27.7M | Buy |
297,437
+132,961
| +81% | +$10.6M | 0.01% | 1032 |
|
|
2020
Q3 | $10.5M | Buy |
164,476
+40,012
| +32% | +$2.34M | ﹤0.01% | 1509 |
|
|
2020
Q2 | $6.49M | Buy |
124,464
+13,709
| +12% | +$588K | ﹤0.01% | 1764 |
|
|
2020
Q1 | $3.46M | Buy |
110,755
+81,615
| +280% | +$2.73M | ﹤0.01% | 2065 |
|
|
2019
Q4 | $977K | Sell |
29,140
-26,999
| -48% | -$858K | ﹤0.01% | 3462 |
|
|
2019
Q3 | $1.66M | Sell |
56,139
-1,676
| -3% | -$54.5K | ﹤0.01% | 2912 |
|
|
2019
Q2 | $1.99M | Buy |
57,815
+19,364
| +50% | +$621K | ﹤0.01% | 2778 |
|
|
2019
Q1 | $1.26M | Buy |
38,451
+5,242
| +16% | +$155K | ﹤0.01% | 3025 |
|
|
2018
Q4 | $797K | Buy |
33,209
+8,055
| +32% | +$227K | ﹤0.01% | 3341 |
|
|
2018
Q3 | $840K | Buy |
25,154
+8,371
| +50% | +$265K | ﹤0.01% | 3503 |
|
|
2018
Q2 | $487K | Buy |
16,783
+625
| +4% | +$17.4K | ﹤0.01% | 3800 |
|
|
2018
Q1 | $416K | Buy |
16,158
+9,680
| +149% | +$262K | ﹤0.01% | 3823 |
|
|
2017
Q4 | $159K | Buy |
6,478
+1,853
| +40% | +$46.9K | ﹤0.01% | 4551 |
|
|
2017
Q3 | $121K | Buy |
4,625
+515
| +13% | +$12.1K | ﹤0.01% | 4869 |
|
|
2017
Q2 | $92K | Buy |
4,110
+700
| +21% | +$14.6K | ﹤0.01% | 4811 |
|
|
2017
Q1 | $71K | Hold |
3,410
| – | – | ﹤0.01% | 4956 |
|
|
2016
Q4 | $58K | Hold |
3,410
| – | – | ﹤0.01% | 5173 |
|
|
2016
Q3 | $68K | Hold |
3,410
| – | – | ﹤0.01% | 5010 |
|
|
2016
Q2 | $57K | Hold |
3,410
| – | – | ﹤0.01% | 5049 |
|
|
2016
Q1 | $60K | Buy |
+3,410
| New | +$58.4K | ﹤0.01% | 5018 |
|
Other funds holding ARKG
JFG
Royal Bank of Canada's ARKG Position: Q2 2026 in Review
Royal Bank of Canada increased its ARK Genomic Revolution ETF (ARKG) stake by 168% in Q2 2026, buying an estimated $2.78M and bringing the position to 139,071 shares worth $5.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2492.
Royal Bank of Canada first reported a position in ARKG in Q1 2016 and has held it in 42 quarters since. The position peaked at $44.1M in Q2 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.
- Royal Bank of Canada held 139,071 shares of ARK Genomic Revolution ETF worth $5.85M as of Q2 2026.
- Royal Bank of Canada bought 87,213 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $2.78M.
- ARK Genomic Revolution ETF made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #2492 holding.
- Royal Bank of Canada first reported a position in ARK Genomic Revolution ETF in Q1 2016 and has held it in 42 quarters since.
- Royal Bank of Canada's ARK Genomic Revolution ETF position peaked at $44.1M in Q2 2021.
- 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.